Health News

The first few times that scientists mapped out all the DNA in a human being in 2001, each effort cost hundreds of millions of dollars and involved more than 250 people. Even last year, when the lowest reported cost was $250,000, genome sequencing still required almost 200 people. In a paper published online Aug. 9 by Nature Biotechnology, a Stanford University professor reports sequencing his entire genome for less than $50,000 and with a team of just two other people.

Read more

Filed under: Pharmacy News
Tags: DNA, Online, Pharmacy

Related posts

• Chronic inflammation combines with DNA methylation to promote development of colorectal cancer (0)
  Chronic inflammation combines with DNA methylation, a process that shuts down cancer-fighting genes, to promote development of colorectal cancer, scientists at The University of Texas MD Anderson Cancer Center report today in the advance online publication of the journal Nature Medicine. Read more [tags] Pharmacy News [/tags]
  
  
• [11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment (0)
  Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer’s disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer [...]
  
  
• ZyGEM Releases Data Confirming Its PrepGEM(R) Bacteria Kit Is A Simple, Universal Method For Extracting DNA From Different Bacteria Species (0)
  ZyGEM Corp. Ltd., a provider of innovative enzyme-based products for DNA extraction and other life sciences applications, today announced the availability of a new application note documenting that its prepGEM(R) Bacteria DNA extraction kit is capable of producing high quality, ready-to-analyze DNA from a broad range of bacterial species, including mixed or unknown sample types. Read [...]
  
  
• ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate. Read more [tags] Pharmacy News [/tags]
  
  
• ZIOPHARM receives European patent allowance for palifosfamide to treat cancer (0)
  ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer. Read more [tags] Pharmacy [...]